BACKGROUND: Cardiac retransplantation is the definitive treatment for allograft failure despite decreased long-term survival in these patients. The cause of the poorer outcomes in cardiac retransplant patients is unclear. METHODS: This study was a retrospective analysis of 859 adult cardiac transplant patients. Of these, 45 (5.7%) underwent cardiac retransplantation at 8.2 +/- 5.3 (mean +/- SD) years after the first transplant, primarily for severe transplant vasculopathy (n = 42). RESULTS: One-year survival for retransplant patients was significantly lower compared with de novo transplant patients (75% vs 87%; p < 0.003). Twenty-three patients died due to either malignancy (n = 8), infection (n = 6), rejection (n = 3), sudden death (n = 2), recurrent transplant coronary artery disease (n = 2) or post-operative bleeding (n = 1). CONCLUSION: Although cardiac retransplantation has immediate life-saving benefits, survival is lower compared with de novo cardiac transplantation due to higher rates of malignancy and infection.
BACKGROUND: Cardiac retransplantation is the definitive treatment for allograft failure despite decreased long-term survival in these patients. The cause of the poorer outcomes in cardiac retransplant patients is unclear. METHODS: This study was a retrospective analysis of 859 adult cardiac transplant patients. Of these, 45 (5.7%) underwent cardiac retransplantation at 8.2 +/- 5.3 (mean +/- SD) years after the first transplant, primarily for severe transplant vasculopathy (n = 42). RESULTS: One-year survival for retransplant patients was significantly lower compared with de novo transplant patients (75% vs 87%; p < 0.003). Twenty-three patients died due to either malignancy (n = 8), infection (n = 6), rejection (n = 3), sudden death (n = 2), recurrent transplant coronary artery disease (n = 2) or post-operative bleeding (n = 1). CONCLUSION: Although cardiac retransplantation has immediate life-saving benefits, survival is lower compared with de novo cardiac transplantation due to higher rates of malignancy and infection.
Authors: Kevin J Clerkin; Sunu S Thomas; Jennifer Haythe; P Christian Schulze; Maryjane Farr; Hiroo Takayama; Ulrich P Jorde; Susan W Restaino; Yoshifumi Naka; Donna M Mancini Journal: J Heart Lung Transplant Date: 2014-09-28 Impact factor: 10.247
Authors: Aya Saito; Richard J Novick; Bob Kiaii; F Neil McKenzie; Mackenzie Quantz; Peter Pflugfelder; Grant Fisher; Michael W A Chu Journal: Can J Surg Date: 2013-02 Impact factor: 2.089
Authors: Syed-Saif Abbas Rizvi; Jessica G Y Luc; Jae Hwan Choi; Kevin Phan; Ester Moncho Escrivà; Sinal Patel; H Todd Massey; Vakhtang Tchantchaleishvili Journal: Ann Cardiothorac Surg Date: 2018-01
Authors: Jill Savla; Kimberly Y Lin; Madhura Pradhan; Rebecca L Ruebner; Rachel S Rogers; Somaly S Haskins; Anjali T Owens; Peter Abt; J William Gaynor; Robert E Shaddy; Joseph W Rossano Journal: J Am Heart Assoc Date: 2015-12-11 Impact factor: 5.501